株式会社MOLCURE
Founded 2013 · 21 employees on LinkedIn · 4 known investors
MOLCURE uses proprietary large language models, physics-based simulations, and experimental data from its in-house biolab to discover antibody and peptide biotherapeutics against difficult targets. It offers an AI-driven drug discovery platform covering high-throughput screening, next-generation sequencing, de novo molecule discovery, and lead optimization for pharmaceutical partners.
Founders & leadership
株式会社MOLCURE was founded in 2013 by Satoshi Tamaki and Ryu Ogawa.
Investors · 4
Frequently asked questions
- What does 株式会社MOLCURE do?
- MOLCURE uses proprietary large language models, physics-based simulations, and experimental data from its in-house biolab to discover antibody and peptide biotherapeutics against difficult targets. It offers an AI-driven drug discovery platform covering high-throughput screening, next-generation sequencing, de novo molecule discovery, and lead optimization for pharmaceutical partners.
- Who founded 株式会社MOLCURE?
- 株式会社MOLCURE was founded by Satoshi Tamaki, Ryu Ogawa in 2013.
- Who are 株式会社MOLCURE's investors?
- 株式会社MOLCURE's investors include GMO VenturePartners, Japan Post Capital Co. Ltd., STRIVE, UTEC.